The emergence of antibiotic-resistant and food-spoilage microorganisms has renewed efforts to identify safe and natural alternative agents of antibiotics such as probiotics. The aim of this study was the isolation of lactobacilli as potential probiotics from local dairy products with broad antibacterial and anti-biofilm activities against antibiotic-resistant strains of Pseudomonas aeruginosa and determination of their inhibition mechanism. Antibiotic susceptibility and classification of acquired resistance profiles of 80 P. aeruginosa strains were determined based on Centers for Disease Control and Prevention (CDC) new definition as multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) followed by antibacterial assessment of lactobacilli against them by different methods. Among the 80 P. aeruginosa strains, 1 (1.3%), 50 (62.5%), and 78 (97.5%) were PDR, XDR, and MDR, respectively, and effective antibiotics against them were fosfomycin and polymyxins. Among 57 isolated lactobacillus strains, two strains which were identified as Lactobacillus fermentum using biochemical and 16S rDNA methods showed broad inhibition/killing and anti-biofilm effects against all P. aeruginosa strains. They formed strong biofilms and had bile salts and low pH tolerance. Although investigation of inhibition mechanism of these strains showed no bacteriocin production, results obtained by high-performance liquid chromatography (HPLC) analysis indicated that their inhibitory effect was the result of production of three main organic acids including lactic acid, acetic acid, and formic acid. Considering the broad activity of these two L. fermentum strains, they can potentially be used in bio-control of drug-resistant strains of P. aeruginosa.
There were high levels of antibiotic resistance and a high frequency of multi-drug resistance and extensive-drug resistance profiles, as well as highly prevalent blaNDM-1 genes in the bacteria investigated.
BACKGROUND
Cholecystitis is a common surgical condition. Recently, several authors have reported that
DNA of bile tolerant Helicobacter spp. has been found in the human bile colonizing the biliary
tract. The aim of this study was to evaluate the association between the presence of Helicobacter
spp. and gallstone cholecystitis.
METHODS
In this case-control study, gallstones, bile, and gallbladder mucosa were collected from 25
patients without gallstone disease, 24 with acute cholecystitis, and 28 with chronic cholecystitis.
The presence of
Helicobacter pylori (H. pylori), Helicobacter bilis (H. bilis), Helicobacter hepaticus
(H. hepaticus)
, and Helicobacter pullorum (H. pullorum) were investigated by polymerase chain
reaction (PCR) using species-specific primers.
RESULTS
In this study, 77 subjects with acute and chronic cholecystitis and control groups with a mean
age of 46.85 ± 14.53 years, including 58 (67.25%) women and 19 (32.75%) men were included.
DNA of 10 Helicobacter spp. was detected in the bile of the patients with cholecystitis including
eight H. pylori and two H. bilis. However, we could not detect H. hepaticus and H. pullorum DNA in
the samples. Moreover, there was an association between H. pylori and acute cholecystitis (p = 0.048),
which was found to be stronger in 31-40-year-olds group (p = 0.003).
CONCLUSION
We found an association between the presence of H. pylori DNA and acute gallstone cholecystitis.
There is not statistically significant correlation between three enterohepatic Helicobacter spp. (
H.
bilis, H. hepaticus
, and H. pullorum) and cholelithiasis. Given the low sample size of the patients,
more studies are required to clear the clinical role of Helicobacter spp. in the gallstone disease
and cholecystitis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.